Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 76.9% during the third quarter, Holdings Channel.com reports. The fund owned 1,969,169 shares of the biopharmaceutical company’s stock after acquiring an additional 856,200 shares during the period. Handelsbanken Fonder AB’s holdings in Halozyme Therapeutics were worth $112,715,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in HALO. Campbell & CO Investment Adviser LLC grew its position in Halozyme Therapeutics by 12.3% in the 4th quarter. Campbell & CO Investment Adviser LLC now owns 17,369 shares of the biopharmaceutical company’s stock valued at $642,000 after acquiring an additional 1,904 shares in the last quarter. Epoch Investment Partners Inc. grew its holdings in shares of Halozyme Therapeutics by 250.5% in the fourth quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock valued at $42,986,000 after purchasing an additional 831,199 shares in the last quarter. Prudential PLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $1,248,000. Aurora Investment Counsel increased its stake in Halozyme Therapeutics by 5.4% during the 4th quarter. Aurora Investment Counsel now owns 37,156 shares of the biopharmaceutical company’s stock worth $1,373,000 after buying an additional 1,895 shares during the period. Finally, Neo Ivy Capital Management acquired a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $207,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have commented on HALO. TD Cowen boosted their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. The Goldman Sachs Group upped their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a report on Monday, July 22nd. Benchmark reaffirmed a “buy” rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research report on Friday, June 7th. Finally, Piper Sandler downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $48.00 to $51.00 in a research note on Friday, June 7th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.00.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded down $1.25 during trading on Friday, reaching $59.18. The company had a trading volume of 1,090,396 shares, compared to its average volume of 1,270,675. Halozyme Therapeutics, Inc. has a fifty-two week low of $32.83 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 5.19, a current ratio of 7.41 and a quick ratio of 6.21. The stock’s fifty day moving average price is $58.96 and its 200 day moving average price is $50.28. The firm has a market capitalization of $7.53 billion, a price-to-earnings ratio of 24.45, a price-to-earnings-growth ratio of 0.56 and a beta of 1.27.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. Halozyme Therapeutics’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.68 EPS. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, CFO Nicole Labrosse sold 5,000 shares of the company’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the transaction, the chief financial officer now owns 15,480 shares of the company’s stock, valued at $834,836.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CFO Nicole Labrosse sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares in the company, valued at $834,836.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $55.12, for a total transaction of $551,200.00. Following the sale, the senior vice president now directly owns 168,176 shares in the company, valued at approximately $9,269,861.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 84,881 shares of company stock valued at $4,932,284. 2.40% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.